CRISPR Therapeutics AG (CRSP) vs Definium Therapeutics, Inc. (DFTX)
A side-by-side comparison of CRISPR Therapeutics AG and Definium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$54.59HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
DFTX
Definium Therapeutics, Inc.
$35.26HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — CRSP vs DFTX
growth of $100 · dividends reinvested · last 10yCRSP +225.8% (+12.5%/yr)DFTX +971.9% (+26.8%/yr)DFTX compounded faster over this window
CRSP DFTX
CRSP vs DFTX: by the numbers
- •CRSP is the larger company ($5.27B vs $4.68B market cap).
- •Both run net losses; DFTX's is the smaller (0.00% vs -3368.72% net margin).
Metrics side by side
Valuation
| Metric | CRSP | DFTX |
|---|---|---|
| P/S ratio | 393.16 | N/A |
| P/B ratio | 3.01 | 5.09 |
Profitability
| Metric | CRSP | DFTX |
|---|---|---|
| Gross margin | -6537.01% | 0.00% |
| Operating margin | -16191.40% | 0.00% |
| Net margin | -3368.72% | 0.00% |
| ROE | -25.83% | -38.51% |
| ROIC | -21.12% | -23.81% |
Growth (annualized)
| Metric | CRSP | DFTX |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | N/A |
| Total return CAGR (5Y) | -10.97% | 1.43% |
Frequently asked
- How have CRSP and DFTX total returns compared?
- Over the past 5 years, CRSP delivered -10.97% and DFTX delivered 1.43% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
CRISPR Therapeutics AG ROEDefinium Therapeutics ROECRISPR Therapeutics AG operating marginDefinium Therapeutics operating marginCRISPR Therapeutics AG revenue growthDefinium Therapeutics revenue growthCRISPR Therapeutics AG free cash flowDefinium Therapeutics free cash flow
CRISPR Therapeutics AG & Definium Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.